Gleevec Decreases Cancer Recurrence For Patients With Primary Gastrointestinal Stromal Tumor

Armen Hareyan's picture

Primary Gastrointestinal Stromal Tumor

Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor, a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.